Abstract 16248: Attitudes Towards Genetic Testing and Genome Sequencing in the MI GENES Randomized Control Study
Background: Genetic testing and genome sequencing are being increasingly used in the clinical setting. However, patients’ attitudes towards genetic testing and genome sequencing after disclosure of the cardiovascular (CHD) risk are unknown.
Methods: We investigated attitudes towards genetic testing and genome sequencing in participants aged 45-65 years at 10-year intermediate risk for CHD and not on statins. Participants were identified from the Mayo Clinic Bio-bank and randomly assigned to receive either a conventional risk estimate (CRS arm) or a conventional risk estimate along with a genetic risk score based on 28 genetic risk variants for CHD (GRS arm). Risk was disclosed by a genetic counselor followed by shared decision-making regarding statin use with a physician. Participants completed surveys on attitudes towards genetic testing and genome sequencing after risk disclosure. Questions related to attitudes towards genetic testing were scored on a 5-point Likert scale from totally disagree to totally agree. Questions related to genome sequencing were scored “Yes” as favorable and “No or Not sure” as unfavorable.
Results: Significant majority of participants had favorable views towards genetic testing (93%) and genome sequencing (91%) for CHD. There was no difference in mean favorable score for genetic testing between CRS and GRS groups (26.13 ± 5.23 vs. 26.46 ± 4.84; p=0.635). Participants in both the CRS and GRS arms had similarly favorable attitudes towards genome sequencing (93% vs. 90%, p=0.129).
Conclusion: Participants in this clinical trial of disclosing genetic risk of CHD had favorable attitudes towards genetic testing and genome sequencing. Disclosure of GRS did not significantly impact attitudes towards genetic testing and genome sequencing in individuals at intermediate risk for CHD.
Author Disclosures: S. Kattel: None. M. Jamaliramin: None. S. Brown: None. H. Jouni: None. E. Austin: None. I.J. Kullo: Research Grant; Significant; NHGRI.
- © 2016 by American Heart Association, Inc.